Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug

Allegro Appoints New CEO and Prepares for Ph III Trials for Diabetic Macular Edema Drug

Source: 
CP Wire
snippet: 
  • New CEO Has 25 Years Experience in the ophthalmic pharmaceutical space
  • Luminate met primary endpoints in Ph IIb study
  • Luminate is a first-in-class integrin peptide therapy for treating neovascular retinal diseases